EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Dose‐intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial

Matthias Guckenberger iD, Charlotte Billiet iD, Daniel Schnell, Ciro Franzese iD, Mateusz Spałek iD, Susanne Rogers, Jean-Jacques Stelmes iD, Daniel M Aebersold iD, Hossein Hemmatazad, Frank Zimmermann, Jörg Zimmer, Thomas Zilli iD und 6 weitere

Cancer · 2024-08 · 130 (15) · 2713-2722

DOI: 10.1002/cncr.35310 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer, online erschienen am 06.04.2024. Verfasst von Matthias Guckenberger und 17 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Radiosurgery, Spinal Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swiss Cancer Research Foundation, Varian Medical Systems.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The purpose of this randomised study was to determine whether dose‐intensified stereotactic body radiotherapy (SBRT) for painful vertebral metastases results in increased rates of pain improvement compared with conventional external beam radiotherapy (cEBRT) (control) 6 months after treatment.

Methods

This randomized, controlled phase 3 trial was conducted between November 2016 and January 2023, when it was stopped early. Patients were eligible if they were aged 18 years or older; had one or two painful, stable, or potentially unstable vertebral metastases; and had a life expectancy of 1 year or longer according to the investigator's estimates. Patients received 48.5 grays (Gy) in 10 fractions (with epidural involvement) or 40 Gy in five fractions (without epidural involvement) in the SBRT group and 30 Gy in 10 fractions or 20 Gy in five fractions in the cEBRT group, respectively. The primary end point was an improvement in the pain score at the treated site by at least 2 points (on a visual analog scale from 0 to 10 points) at 6‐month follow‐up. Data were analyzed on an intention‐to‐treat and per‐protocol basis.

Results

Of 214 patients who were screened for eligibility, 63 were randomized 1:1 between SBRT (33 patients with 36 metastases) and cEBRT (30 patients with 31 metastases). The median age of all patients was 66 years, and 40 patients were men (63.5%). In the intention‐to‐treat analysis, the 6‐month proportion of patients who had metastases with pain reduction by 2 or more points was significantly higher in the SBRT group versus the control group (69.4% vs. 41.9%, respectively; two‐sided p = .02). Changes in opioid medication intake relative to baseline were nonsignificant between the groups. No differences were observed in vertebral compression fracture or adverse event rates between the groups.

Conclusions

Dose‐intensified SBRT improved pain score more effectively than cEBRT at 6 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgerySpinal NeoplasmsHumansMaleFemaleAgedMiddle AgedPain MeasurementCancer PainAged, 80 and overDose Fractionation, RadiationTreatment OutcomeRadiotherapy Dosage

Stichwörter der Autor:innen

bone metastasesconventional external beam radiotherapypainstereotactic body radiotherapy (SBRT)vertebral metastases

Autor:innen und Institutionen

  • University Hospital Zurich, Zurich, Switzerland.
  • University of Zurich, Zurich, Switzerland.
  • Iridium Netwerk, University of Antwerp, Antwerp, Belgium.
  • University Hospital Freiburg, Freiburg, Germany.
  • Humanitas University, Humanitas Research Hospital IRCCS, Milan, Italy.
  • Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

ORCID-Profile: Matthias Guckenberger, Charlotte Billiet, Ciro Franzese, Mateusz Spałek, Jean-Jacques Stelmes, Daniel M Aebersold, Thomas Zilli, Alessio Bruni, Brigitta G Baumert

Förderung

  • Swiss Cancer Research Foundation
  • Varian Medical Systems

Zitieren

APA

Guckenberger, M., Billiet, C., Schnell, D., Franzese, C., Spałek, M., Rogers, S., Stelmes, J. J., Aebersold, D. M., Hemmatazad, H., Zimmermann, F., Zimmer, J., Zilli, T., Bruni, A., Baumert, B. G., Nägler, F., Gut, P., Förster, R., & Madani, I. (2024). Dose‐intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial. Cancer, 130(15), 2713-2722. https://doi.org/10.1002/cncr.35310

Vancouver

Guckenberger M, Billiet C, Schnell D, Franzese C, Spałek M, Rogers S, et al. Dose‐intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial. Cancer. 2024;130(15):2713-2722. doi:10.1002/cncr.35310

BibTeX
@article{Guckenberger2024,
  author = {Guckenberger, Matthias and Billiet, Charlotte and Schnell, Daniel and Franzese, Ciro and Spałek, Mateusz and Rogers, Susanne and Stelmes, Jean-Jacques and Aebersold, Daniel M and Hemmatazad, Hossein and Zimmermann, Frank and Zimmer, Jörg and Zilli, Thomas and Bruni, Alessio and Baumert, Brigitta G and Nägler, Franziska and Gut, Philipp and Förster, Robert and Madani, Indira},
  title = {Dose‐intensified stereotactic body radiotherapy for painful vertebral metastases: A randomized phase 3 trial},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {15},
  pages = {2713--2722},
  doi = {10.1002/cncr.35310}
}
Kostenlos starten →